Predicting Response to Anthracyclines in Ovarian Cancer

(1) Background: Anthracyclines are intriguing drugs, representing one of the cornerstones of both first and subsequent-lines of chemotherapy in ovarian cancer (OC). Their efficacy and mechanisms of action are related to the hot topics of OC clinical research, such as BRCA status and immunotherapy. P...

Full description

Saved in:
Bibliographic Details
Published in:International journal of environmental research and public health 2022-04, Vol.19 (7), p.4260
Main Authors: Ferrero, Annamaria, Borghese, Martina, Restaino, Stefano, Puppo, Andrea, Vizzielli, Giuseppe, Biglia, Nicoletta
Format: Article
Language:English
Subjects:
Alopecia
Anthracycline
Anthracyclines - therapeutic use
Antibiotics, Antineoplastic - pharmacology
Antibiotics, Antineoplastic - therapeutic use
Antitumor activity
Apoptosis
Baldness
Breast cancer
Cancer therapies
Carcinoma, Ovarian Epithelial - drug therapy
Cardiotoxicity
Chemotherapy
Doxorubicin - pharmacology
Doxorubicin - therapeutic use
Drug dosages
Drugs
ErbB-2 protein
Free radicals
Histology
Humans
Immunotherapy
Markers
Medical prognosis
Mucositis
Mutation
Organoids
Ovarian cancer
Ovarian carcinoma
Ovarian Neoplasms - drug therapy
Pharmacokinetics
Polyethylene Glycols - pharmacology
Response rates
Review
Systematic review
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:(1) Background: Anthracyclines are intriguing drugs, representing one of the cornerstones of both first and subsequent-lines of chemotherapy in ovarian cancer (OC). Their efficacy and mechanisms of action are related to the hot topics of OC clinical research, such as BRCA status and immunotherapy. Prediction of response to anthracyclines is challenging and no markers can predict certain therapeutic success. The current narrative review provides a summary of the clinical and biological mechanisms involved in the response to anthracyclines. (2) Methods: A MEDLINE search of the literature was performed, focusing on papers published in the last two decades. (3) Results and Conclusions: BRCA mutated tumors seem to show a higher response to anthracyclines compared to sporadic tumors and the severity of hand-foot syndrome and mucositis may be a predictive marker of PLD efficacy. CA125 can be a misleading marker of clinical response during treatment with anthracyclines, the response of which also appears to depend on OC histology. Immunochemistry, in particular HER-2 expression, could be of some help in predicting the response to such drugs, and high levels of mutated p53 appear after exposure to anthracyclines and impair their antitumor effect. Finally, organoids from OC are promising for drug testing and prediction of response to chemotherapy.
ISSN:1660-4601
1661-7827
1660-4601
DOI:10.3390/ijerph19074260